FindTrial
Sign In

Apremilast 30mg

DRUG14 trials

Sponsors

Amgen, Can-Fite BioPharma, NHS Greater Glasgow and Clyde, Tulane University, University of Zurich

Conditions

Alopecia AreataChronic Hand DermatitisDermatomyositis, Adult TypePlaque PsoriasisPlaque-type PsoriasisPsoriasisPsoriasis VulgarisPsoriasis of Scalp

Phase 2

Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
CompletedNCT00773734
AmgenPlaque-type Psoriasis, Psoriasis
Start: 2008-09-01End: 2015-05-20Updated: 2020-05-07
Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis
CompletedNCT03529955
Tulane UniversityDermatomyositis, Adult Type
Start: 2018-06-12End: 2021-04-07Updated: 2023-03-03

Phase 3

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
CompletedNCT01172938
AmgenPsoriatic Arthritis
Start: 2010-06-02End: 2016-10-27Updated: 2020-06-19
PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
CompletedNCT01212757
AmgenPsoriatic Arthritis
Start: 2010-09-27End: 2017-01-25Updated: 2020-05-06
PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
CompletedNCT01212770
AmgenPsoriatic Arthritis
Start: 2010-09-30End: 2017-02-09Updated: 2020-05-06
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
CompletedNCT01307423
AmgenPsoriatic Arthritis
Start: 2010-12-09End: 2017-08-16Updated: 2022-06-14
CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis
CompletedNCT03168256
Can-Fite BioPharmaPlaque Psoriasis
Start: 2018-09-15End: 2022-04-27Updated: 2022-06-28

Phase 4

Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis
NCT03553433
University of ZurichPsoriasis of Scalp, Psoriasis Vulgaris
Start: 2018-06-30End: 2020-06-30Target: 90Updated: 2018-06-12
Apremilast for RAS
CompletedNCT03690544
Mayo ClinicRecurrent Aphthous Stomatitis
Start: 2018-10-12End: 2021-07-14Updated: 2022-07-14
Apremilast and Moderate to Severe Chronic Hand Dermatitis
WithdrawnNCT03741933
George Washington UniversityChronic Hand Dermatitis
Start: 2019-02-28End: 2019-08-01Updated: 2023-01-11
The Maintenance Effect of Enstilar Foam in Combination With Otezla
NCT04555707
Derm Research, PLLCPsoriasis
Start: 2020-06-24End: 2021-09-30Target: 30Updated: 2020-10-09
Efficacy of Oral Apremilast in the Treatment of Alopecia Areata at the Tertiary Care Hospital, Karachi.
CompletedNCT05926882
Jinnah Postgraduate Medical CentreAlopecia Areata
Start: 2022-08-01End: 2023-06-20Updated: 2023-07-03
Efficacy and Safety of Apremilast in Psoriasis
CompletedNCT06032858
Ghurki Trust and Teaching HospitalPsoriasis
Start: 2022-03-06End: 2023-08-10Updated: 2023-09-13

Unknown Phase

Immune Metabolic Associations in Psoriatic Arthritis
CompletedNCT03399708
NHS Greater Glasgow and ClydePsoriasis, Psoriatic Arthritis
Start: 2017-06-12End: 2019-10-25Updated: 2019-11-25

Related Papers

Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (<scp>COMFORT</scp>‐1)
Journal of the European Academy of Dermatology and Venereology2024-01-2627 citations
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
American Journal of Clinical Dermatology2023-06-1440 citations
Apremilast in Recalcitrant Cutaneous Dermatomyositis
JAMA Dermatology2022-10-0525 citations
Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials.
PubMed2021-12-012 citations
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients
Lara D. Veeken2021-06-0711 citations
Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis
Arthritis Research & Therapy2019-05-1076 citations
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies
RMD Open2018-06-0137 citations
Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial
Lara D. Veeken2018-02-0998 citations
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
2016-12-19129 citations
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
The Journal of Rheumatology2016-07-15206 citations
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
2016-01-20193 citations
Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis
The Journal of Rheumatology2015-01-15133 citations
APR Improves PsA Symptoms Out to Week 104
MD Conference Express2014-12-01
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
2014-03-04302 citations
Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.
2013-05-1052 citations
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
2012-06-29191 citations